Fenofibric acid

Catalog No.S4527 Synonyms: NSC 281318, Trilipix, FNF acid

For research use only.

Fenofibric acid (NSC 281318, Trilipix, FNF acid) is a fibrate that acts as a lipid-lowering agent, decreasing low-density lipoprotein cholesterol and triglycerides.

Fenofibric acid Chemical Structure

CAS No. 42017-89-0

Selleck's Fenofibric acid has been cited by 1 Publication

Purity & Quality Control

Choose Selective PPAR Inhibitors

Other PPAR Products

Biological Activity

Description Fenofibric acid (NSC 281318, Trilipix, FNF acid) is a fibrate that acts as a lipid-lowering agent, decreasing low-density lipoprotein cholesterol and triglycerides.
PPARα [1]
In vitro

Fibric acids, active forms of fibrate drugs and activators of peroxisome proliferator-activated receptor-alpha (PPARα), are also known for an HDL-raising effect. Fibric acids enhance fatty acid catabolism and accordingly reduce plasma lipid level, predominantly triglyceride (TG). Fenofibric acid increases the expression of ABCA1 and apoA-I–mediated HDL production. The effect on ABCA1 expression was through the enhancement of the transcription of the ABCA1 gene being dependent on LXR[1].

In vivo Fenofibric acid attenuates aberrant increases of circulating EPC(Endothelial Progenitor Cells) in OIR mice. Inhibitory effect of Fenofibric acid on EPC mobilization in the OIR model is PPARα-dependent.Fenofibric acid Inhibits hypoxia-induced retinal EPC increase in a PPARα-dependent manner. Fenofibric acid decreases CXCR4-positive EPC in the circulation, downregulates the serum SDF-1 level and suppresses HIF-1a and SDF-1 overexpression in the retina[1].

Protocol (from reference)

Cell Research:


  • Cell lines: RAW264 cells; THP-1 cells
  • Concentrations: 0-200 μmol/L
  • Incubation Time: 48 h
  • Method:

    PPAR activators fenofibric acid is dissolved in DMSO and added to the culture medium containing 0.2% BSA. RAW264 cells are washed with PBS and cultured an additional 48 hours in the presence of fenofibric acid in DMEM/F-12(1:1) medium containing 2% TCM and 0.2% BSA. During the last 24 hours of the drug treatment, 300 mol/L of dibutyryl cAMP and apoA-I (10 μg/mL) are added to the medium. THP-1 cells are also treated with the compound and apoA-I in 0.2% BSA-RPMI 1640 medium and 0.1% BSA-MEM. Cholesterol and choline-phospholipid released into the medium by apoA-I are determined enzymatically. Adherent cells are dissolved in 0.1 N NaOH for protein determination by bicinchoninic acid protein assay system.

Animal Research:


  • Animal Models: C57BL/6J; PPARa-/- mice
  • Dosages: 10 mg/kg
  • Administration: i.p.

Solubility (25°C)

In vitro

Chemical Information

Molecular Weight 318.75


CAS No. 42017-89-0
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles CC(C)(C(=O)O)OC1=CC=C(C=C1)C(=O)C2=CC=C(C=C2)Cl

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03382756 Completed Dietary Supplement: High fat diet|Drug: CKD-337 Dyslipidemias Chong Kun Dang Pharmaceutical October 12 2017 Phase 1
NCT02891408 Completed Drug: Firsocostat|Drug: Fenofibrate Nonalcoholic Steatohepatitis (NASH) Gilead Sciences September 23 2016 Phase 1
NCT02651753 Completed Drug: Lipitor + Lipidil supra|Drug: CKD-337 Dyslipidemia Chong Kun Dang Pharmaceutical January 2016 Phase 1
NCT02422030 Completed Drug: Lipitor Tab. 40mg|Drug: Trilipix 135mg Healthy Chong Kun Dang Pharmaceutical March 17 2015 Phase 1

(data from https://clinicaltrials.gov, updated on 2022-01-17)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Fenofibric acid | Fenofibric acid ic50 | Fenofibric acid price | Fenofibric acid cost | Fenofibric acid solubility dmso | Fenofibric acid purchase | Fenofibric acid manufacturer | Fenofibric acid research buy | Fenofibric acid order | Fenofibric acid mouse | Fenofibric acid chemical structure | Fenofibric acid mw | Fenofibric acid molecular weight | Fenofibric acid datasheet | Fenofibric acid supplier | Fenofibric acid in vitro | Fenofibric acid cell line | Fenofibric acid concentration | Fenofibric acid nmr